Preliminary safety and pharmacokinetics of a new lysosomotropic oral agent, GNS561, in a first-in-human study in advanced primary liver cancer patients

Meeting Abstract: 745P

A Awada , J Harding , Nuria Kotecki , P Aftimos , T. Decaens , C. Dreyer , Christelle Ansaldi , M Rachid , C. Serdjebi , Philippe Halfon (1, 2) , G Abou-Alfa , E Raymond

1 MEPHI - Microbes évolution phylogénie et infections
2 ALPHABIO - Laboratoire de biologie médicale

Domains: Life Sciences [q-bio]; Microbiology and Parasitology; Bacteriology; Life Sciences [q-bio]; Microbiology and Parasitology; Virology; Life Sciences [q-bio]; Microbiology and Parasitology; Parasitology; Life Sciences [q-bio]; Human health and pathology; Cardiology and cardiovascular system; Life Sciences [q-bio]; Human health and pathology; Emerging diseases; Life Sciences [q-bio]; Human health and pathology; Infectious diseases

A Awada, J Harding, Nuria Kotecki, P Aftimos, T. Decaens, et al.. Preliminary safety and pharmacokinetics of a new lysosomotropic oral agent, GNS561, in a first-in-human study in advanced primary liver cancer patients. 44th Congress of the European-Society-for-Medical-Oncology (ESMO), Sep 2019, Barcelona, Spain. pp.286. ⟨hal-02463220⟩